- Inactivated Vaccines
- Live Attenuated Vaccines
- Subunit
- Conjugate Vaccines
- Others
Preventive Vaccines Market size was valued at USD 88,430.0 million in 2023 and projected to reach at USD 97,519.8 million by 2030 is poised to grow at 1.4% CAGR from 2024-2030. Ongoing worldwide initiatives and vaccination programs, sponsored by organizations such as the World Health Organization (WHO) and Gavi, the Vaccine Alliance, play critical roles in promoting immunization and increasing access to preventative vaccines. These programs help to raise knowledge and adoption of vaccines worldwide. Furthermore, advances in vaccine production technologies, such as recombinant DNA technology, mRNA-based vaccines, and vector-based vaccinations, have resulted in the creation of more effective and targeted preventive vaccines. Continuous innovation improves vaccine efficacy, safety, and scalability.
Preventive Vaccines Market Key Developments:
- In August 2022, Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination from AstraZeneca, has been licensed in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection.
- In June 2022, The United Kingdom Medicines, and Healthcare Products Regulatory Agency (MHRA) has approved the VBI Vaccines' PreHevbri (Hepatitis B vaccine (recombinant, adsorbed)) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. The vaccine is projected to be available in the United Kingdom by 2023.
Preventive Vaccines Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
1.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Preventive Vaccines Market Dynamics
Rising prevalence of infectious diseases are the primary factor driving demand for preventative vaccinations throughout the forecast period. According to the Global Tuberculosis Report 2021, published by WHO in October 2021, most tuberculosis cases were found in the WHO regions of Southeast Asia (43%), Africa (25%), and Western Pacific (18%), with fewer cases found in the Eastern Mediterranean (8.3%) and Europe (2.3%). Thus, the increased prevalence of tuberculosis in the population enhances the demand for prevention, which is expected to drive market growth throughout the forecast period. Furthermore, the emergence of genetic engineering, vaccine delivery technologies, and proteomics has accelerated vaccine technological advancements. This is projected to encourage the development of preventative vaccine products, which would help the market grow. However, the danger of adverse effects and the high cost of vaccine development are expected to limit market growth throughout the projection period.
North-America Got Significant Share
Preventive Vaccines Market Regional Analysis
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is expected to grow in the preventive vaccines market over the forecast period due to factors such as rising infectious disease prevalence, increased demand for vaccines, a growing geriatric population at risk of developing infectious diseases, and the presence of key market players. Growing government and international funding to speed the development of preventative vaccinations in the country is also projected to drive market expansion. Furthermore, the developing company's focus on various business tactics, such as collaboration, partnership, agreement, launches, and facility development, among others, is projected to create chances and make preventative vaccinations more available in the marketplace. This is expected to propel market expansion throughout the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Preventive Vaccines Market Segmentation
By Type
By Disease Type
- Measles
- Polio
- Influenza
- Hepatitis
- Mumps
- Others
Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The Preventive Vaccines Market was valued at USD 88,430.0 million in 2023 and is projected to reach USD 97,519.8 million by 2030, growing at a CAGR of 1.4%.
The rising occurrence of infectious diseases such as influenza, hepatitis, polio, measles, and others increase the need for preventative immunizations.
Advances in vaccine development technologies, such as recombinant DNA technology, mRNA-based vaccines, and vector-based vaccines, have resulted in the creation of more effective and targeted preventive vaccines.
Market research is segmented based on type, Disease type, and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
Key Features of the Reports
- The preventive vaccines market report provides granular level information about the Market size, regional Market share, historic Market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
- The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global Preventive Vaccines Market Introduction |
| 2.1.Global Preventive Vaccines Market - Taxonomy |
| 2.2.Global Preventive Vaccines Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Disease Type |
| 2.2.3.Region |
| 3.Global Preventive Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Preventive Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Preventive Vaccines Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Inactivated Vaccines |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Live Attenuated Vaccines |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Subunit |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Conjugate Vaccines |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Preventive Vaccines Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Measles |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Polio |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Influenza |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Hepatitis |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Mumps |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Preventive Vaccines Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Inactivated Vaccines |
| 8.1.2.Live Attenuated Vaccines |
| 8.1.3.Subunit |
| 8.1.4.Conjugate Vaccines |
| 8.1.5.Others |
| 8.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Measles |
| 8.2.2.Polio |
| 8.2.3.Influenza |
| 8.2.4.Hepatitis |
| 8.2.5.Mumps |
| 8.2.6.Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Inactivated Vaccines |
| 9.1.2.Live Attenuated Vaccines |
| 9.1.3.Subunit |
| 9.1.4.Conjugate Vaccines |
| 9.1.5.Others |
| 9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Measles |
| 9.2.2.Polio |
| 9.2.3.Influenza |
| 9.2.4.Hepatitis |
| 9.2.5.Mumps |
| 9.2.6.Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Inactivated Vaccines |
| 10.1.2.Live Attenuated Vaccines |
| 10.1.3.Subunit |
| 10.1.4.Conjugate Vaccines |
| 10.1.5.Others |
| 10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Measles |
| 10.2.2.Polio |
| 10.2.3.Influenza |
| 10.2.4.Hepatitis |
| 10.2.5.Mumps |
| 10.2.6.Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Inactivated Vaccines |
| 11.1.2.Live Attenuated Vaccines |
| 11.1.3.Subunit |
| 11.1.4.Conjugate Vaccines |
| 11.1.5.Others |
| 11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Measles |
| 11.2.2.Polio |
| 11.2.3.Influenza |
| 11.2.4.Hepatitis |
| 11.2.5.Mumps |
| 11.2.6.Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Inactivated Vaccines |
| 12.1.2.Live Attenuated Vaccines |
| 12.1.3.Subunit |
| 12.1.4.Conjugate Vaccines |
| 12.1.5.Others |
| 12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Measles |
| 12.2.2.Polio |
| 12.2.3.Influenza |
| 12.2.4.Hepatitis |
| 12.2.5.Mumps |
| 12.2.6.Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Sanofi |
| 13.2.2.Johnson& Jonson |
| 13.2.3.Moderna Inc |
| 13.2.4.Sinovac Biotech Ltd |
| 13.2.5.Pfizer Inc |
| 13.2.6.GlaxoSmithKline plc |
| 13.2.7.Merck & Co. Inc |
| 13.2.8.CSL Limited |
| 13.2.9.Novartis AG |
| 13.2.10.Bharat Biotech |
| 13.2.11.Serum Institute |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Sanofi
- Johnson& Jonson
- Moderna Inc
- Sinovac Biotech Ltd
- Pfizer Inc
- GlaxoSmithKline plc
- Merck & Co. Inc
- CSL Limited
- Novartis AG
- Bharat Biotech
- Serum Institute